10 diciembre 2014
In patients with metastatic triple-negative breast cancer, infusion of pembrolizumab produced durable responses in almost one out of five patients. One of the 27 patients had a complete response and four had a partial response. Seven more patients had stable disease.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/dxk9sZ3L0So/141210095854.htm
